BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.
Read the full articleYou might also wanna read
FDA Approves VIZZ Eye Drops for Near Vision Improvement in Presbyopia Patients
The first aceclidine-based eye drop to improve near vision in adults with age-related presbyopia, which affects more than 100 million adults
newatlas.com·11mo ago
Researchers Develop Experimental 'Living Eye Drops' Using Engineered Bacteria to Heal Corneas
Researchers engineered living eye drops using bacteria to heal the cornea with one application. Here is how the experimental therapy could t
bit.ly·24d agoGSK ends brain drug alliance with Alector - BioPharma Dive
9 hours ago ... Yet those drugs also disappointed, leading AbbVie to pull back on the alliance in 2022, then exit it entirely in 2025. Over
Human retinas revived and responsive to light 10 hours after death in eye transplant breakthrough
Perfusing donor human retinas with blood and oxygen meant they continued to respond to light for up to 10 hours after death, marking a signi
newscientist.com·11h ago
Life Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucoma
For the first time ever, scientists are attempting to reverse cellular aging in a living patient. The target: incurable vision loss. The ris
popularmechanics.com·13d agoDorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
Conditions : Primary Open-Angle Glaucoma (POAG); Ocular Hypertension Interventions : Combination Product: Preservative-free dorzolamide-timo
Comments
Sign in to join the conversation.
No comments yet. Be the first.